GB744988A - Improvements in preparations of insulin - Google Patents

Improvements in preparations of insulin

Info

Publication number
GB744988A
GB744988A GB262152A GB262152A GB744988A GB 744988 A GB744988 A GB 744988A GB 262152 A GB262152 A GB 262152A GB 262152 A GB262152 A GB 262152A GB 744988 A GB744988 A GB 744988A
Authority
GB
United Kingdom
Prior art keywords
lysine
poly
ornithine
solution
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB262152A
Inventor
Frank Arnold Robinson
Walter Dickinson
Vladimir Petrow
Samuel Wilkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allen and Hanburys Ltd
BDH Chemicals Ltd
Wellcome Foundation Ltd
Boots Pure Drug Co Ltd
Original Assignee
Allen and Hanburys Ltd
BDH Chemicals Ltd
Wellcome Foundation Ltd
Boots Pure Drug Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allen and Hanburys Ltd, BDH Chemicals Ltd, Wellcome Foundation Ltd, Boots Pure Drug Co Ltd filed Critical Allen and Hanburys Ltd
Priority to GB262152A priority Critical patent/GB744988A/en
Publication of GB744988A publication Critical patent/GB744988A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyamides (AREA)

Abstract

The general methods of preparing polyamino acids described by Bergmann et al J. Biol. Chem. Soc. 111 (1935), 245; Katchalski et al JAmer Chem. Soc. 70 (1948) 2094 and Katchalski et al Nature 164 (1949), 1092 are employed in the preparation of polyamino acids having more than 8 amino acid residues per molecule, said polyamino acid being polylysine, poly-ornithine or polyarginine, or a copolymer of lysine or ornithine with each other or with other amino acids selected from valine, phenylalanine, leucine, isoleucine and glycine or guanidization products of said copolymers. The removal of carbobenzoxy groups from the poly-carbobenzoxyamino acid stage of the process is as disclosed in these publications, in which a solution of the polycarbobenzoxypeptide in a suitable anhydrous solvent is treated with anhydrous hydrogen chloride. Examples relate to the preparation of the following: (a) poly-L-lipine hydrochloride; (b) polyornithine hydrochloride having a chain length of at least 10 amino acid residues; (c) polyarginine sulphate having a chain length of at least 10 amino acid residues. (a) L-lipine monohydrochloride is reacted with benzyl chloroformate in aqueous sodium hydroxide at 0 DEG C. to form a :e dicarbobenzyloxyL-lipine (formula II), which is reacted with phosphorus pentachloride in ether to form first a :e -dicarbobenzoxylysyl chloride (III) and then e -carbobenzoxy a -N-carboxy-lysine anhydride (IV). The anhydride is dissolved in benzene and refluxed with a small quantity of water and dioxan. The polymer (V) so produced is dissolved in glacial acetic acid and dry hydrochloric acid is passed for 6 hours at 45-50 DEG C. Poly-L-lysine hydrochloride (VI) is thereby formed. In the polymerization step:pyridine, dioxane, ethylacetate or nitrobenzene may be used in place of the benzene; and ammonia or glycine dimethylamide may be used in place of the water, which initiates the polymerization. In the decarbobenzoxylation step, nitromethane may be used in place of the glacial acetic acid. (b) DL-ornithine hydrobromide is reacted with carbobenzoxy chloride in aqueous sodium hydroxide to form dicarbobenzoxyornithine. The anhydride is formed by treating a benzene solution with phosphorus pentachloride; the polymer by refluxing a benzene solution with water as initiator; and decarbobenzoxylation of the polymer by treating a dioxan solution with dry hydrogen chloride. (c) Polyarginine sulphate is prepared by adding 5-methyl isothiourea sulphate to a solution of polyornithine hydrochloride in ammonia. Co-polymers are produced by polymerizing mixed anhydrides, e.g. e -carbobenzoxy-L-lysine-a -N-carboxy anhydride and d -carbobenzoxy-DL-ornithine-a -N-carboxy anhydride to give poly-(L-lysine:DL-ornithine)-hydrochloride. The polyamines are employed in the preparation of an insulin complex (see Group VI). Specification 518,624 is referred to.ALSO:An insulin product of prolonged effect consists of a complex of insulin with a polyamino acid having more than 8 amino acid residues per molecule, said polyamino acid being poly-lysine, polyornithine or poly-arginine, or a copolymer of lysine or ornithine with each other or with other aminoacids selected from valine, phenylalanine, leucine, isoleucine and glycine, or guanidisation products of said copolymers. The complex is prepared by reacting the insulin and polyaminoacid in solution, e.g. aqueous solution, preferably at the isophane point of said polyamino acid, and preferably at a pH of 5 to 8. The solution may also contain a zinc salt e.g. zinc chloride. The resultant aqueous suspension may be used as such for a pharmaceutical injection, in which case, there may be added (a) isotonics e.g. sodium chloride or glycerol (b) antiseptics e.g. phenol or cresol including tricresol, (c) buffers such as sodium phosphate buffer to any desired pH e.g. 7,1. Alternatively, the complex may be separated from the reaction liquors and then put up in suitable pharmaceutical form. The polyamino acid is produced by a process which includes a one step polymerisation reaction performed on an amino acid derivative, or mixture of amino acid derivatives (see Group IV(b)). Preferably the polyamino acid contains 10 to 15 amino acid residues per molecule. Copolymers containing 25 moles per cent of lysine, ornithine or arginine are preferred. The poly-amino acids may be formed from L-, D- or DL-amino acids. Specification 518,624 is referred to.
GB262152A 1952-01-31 1952-01-31 Improvements in preparations of insulin Expired GB744988A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB262152A GB744988A (en) 1952-01-31 1952-01-31 Improvements in preparations of insulin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB262152A GB744988A (en) 1952-01-31 1952-01-31 Improvements in preparations of insulin

Publications (1)

Publication Number Publication Date
GB744988A true GB744988A (en) 1956-02-15

Family

ID=9742778

Family Applications (1)

Application Number Title Priority Date Filing Date
GB262152A Expired GB744988A (en) 1952-01-31 1952-01-31 Improvements in preparations of insulin

Country Status (1)

Country Link
GB (1) GB744988A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013957A2 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
WO2002053184A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
CN102391505A (en) * 2011-09-06 2012-03-28 天津科技大学 Epsilon-polylysine metal complex and preparation method thereof
US8278264B2 (en) 1999-08-24 2012-10-02 Kai Pharmaceuticals, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US8623833B2 (en) 1999-08-24 2014-01-07 Kai Pharmaceuticals, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013957A2 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
WO2001013957A3 (en) * 1999-08-24 2001-10-04 Cellgate Inc Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US8278264B2 (en) 1999-08-24 2012-10-02 Kai Pharmaceuticals, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US8623833B2 (en) 1999-08-24 2014-01-07 Kai Pharmaceuticals, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US8729010B2 (en) 1999-08-24 2014-05-20 Kai Pharmaceuticals, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
WO2002053184A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
WO2002053184A3 (en) * 2001-01-05 2002-09-19 Intercell Biomedizinische Forschungs & Entwicklungs Gmbh Uses for polycationic compounds as vaccine adjuvants
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
CN102391505A (en) * 2011-09-06 2012-03-28 天津科技大学 Epsilon-polylysine metal complex and preparation method thereof
CN102391505B (en) * 2011-09-06 2013-05-01 天津科技大学 Epsilon-polylysine metal complex and preparation method thereof

Similar Documents

Publication Publication Date Title
Katchalski Poly-α-amino acids
AU764144B2 (en) Polyamide chains of precise length, methods to manufacture them and their conjugates
Zwartouw et al. Polyglutamic acid from Bacillus anthracis grown in vivo: structure and aggressin activity
Katchalski et al. Polyamino acids as protein models
Harada et al. The thermal condensation of glutamic acid and glycine to linear peptides1
Hanby et al. 632. Synthetic polypeptides. Part II. Polyglutamic acid
Sage et al. The serological specificity of the poly-alanine immune system
US2938892A (en) Amides and process of preparing same with a monocarbodhmide
Becker et al. The Synthesis of High Molecular Weight Lysine Polypeptides1, 2
Solovsky et al. Synthesis of N-(2-hydroxypr opyl) methacrylamide copolymers with antimicrobial activity
Salton Studies of the bacterial cell wall VIII. Reaction of walls with hydrazine and with fluorodinitrobenzene
EP1701969B1 (en) Process for peptide synthesis using a reduced amount of deprotection agent
GB744988A (en) Improvements in preparations of insulin
Noguchi et al. A new synthetic method of protein analogs having periodic arrangement of amino acids
Nissen et al. Polydepsipeptides, 4 Synthesis of the alternating Polydepsipeptides Poly (Ala‐Lac) and Poly (Val‐Lac)
Katchalski [81] Procedures for preparation of peptide polymers: I. Preparation of poly-l-lysine
ATE146498T1 (en) POLYMERS SUITABLE AS BINDERS
NO165549B (en) PROCEDURE FOR POWDERING A VINYLAROMATIC MONOMER AND AN ACRYLIC MONOMER ON POLYBUTADIA BY EMULSION POLYMERIZATION.
Coleman 505. Synthetic polypeptides. Part IV. Preparation and polymerisation of oxazolid-2: 5-diones derived from α-amino-dicarboxylic acids
MURAMATU et al. Inhibition of caseinolytic activity of plasmin by various synthetic inhibitors
JPH04502156A (en) Novel TNF-peptide
Kopple et al. The Synthesis of Poly-α-amino Acids in Anhydrous Hydrogen Fluoride1
Nishi et al. Polymerization reaction with diphenylphosphoryl azide. Preparation of poly (α‐amino acid) s by direct polycondensation of α‐amino acids
US3503951A (en) Complexes of a.c.t.h. peptides with polyglutamic and polyaspartic acid
JPH04502315A (en) Novel TNF-peptide